Humpath.com - Human pathology

Home > E. Pathology by systems > Reproductive system > Female genital system > Breast > PIK3CA-mutated mammary carcinoma

PIK3CA-mutated mammary carcinoma

Tuesday 1 November 2016

- PIK3CA-mutated mammary carcinoma

  • PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. (25559818)
  • PIK3CA mutations were identified in 23% of HER2-positive breast tumors, and these mutations were associated with poorer outcome in all of the treatment arms. (25559818)
  • Activating mutations in PIK3CA predicted poor pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant therapies that target HER2. (25559818)
  • Consequently, the combination of anti-HER2 agents and PI3K inhibitors is being investigated.
  • PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (2519975)

Open references

- PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C. J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi : 10.1200/JCO.2014.55.7876 PMID: 25199759